logo-loader
viewImmuPharma PLC

Immupharma PLC assessing best route forward for lead drug Lupuzor

ImmuPharma PLC's (LON:IMM) chairman Tim McCarthy tells Proactive London's Andrew Scott discussions with potential partners are ongoing as they consider the best route forward for its lead drug.

The results from an extension study of Lupuzor, a treatment for the autoimmune disease Lupus, will factor into the decision making.

McCarthy also updates on plans to merge the Elro and Ureka subsidiaries and are looking to out-licence their technologies, or spin off the businesses completely.

Quick facts: ImmuPharma PLC

Price: 7.875 GBX

AIM:IMM
Market: AIM
Market Cap: £13.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

on 11/9/19

2 min read